Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: Review of current status and future perspectives

Sexual Health

Volumn 11, Issue 6, 2014, Pages 511-523

  Toft, Lars ^a   Tolstrup, Martin ^a   Storgaard, Merete ^a   Østergaard, Lars ^a   Søgaard, Ole S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

anal cancer; cervical cancer; genital warts; immunisation.

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; WART VIRUS VACCINE;

ADULT; ANTIVIRAL THERAPY; CARCINOGENICITY; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; PEER REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VACCINATION;

EID: 84914108965     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH14015     Document Type: Review

References (51)

1. Forman D, De Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl): F12-23. doi:10.1016/j.vaccine. 2012.07.055
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. doi:10.1016/S0140-6736(07)61050-2
3. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19
4. Denny LA, Franceschi S, De Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30(Suppl): F168-74. doi:10.1016/j.vaccine.2012.06.045
5. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026-34. doi:10.1093/cid/cir1012
6. De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56. doi:10.1016/S1470-2045(10) 70230-8
7. Munoz N, Castellsague X, De Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl): S3/1-10
8. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer 2014; 134: 1389-98. doi:10.1002/ijc.28425
9. De Vuyst H, Ndirangu G, Moodley M, Tenet V, Estambale B, Meijer CJ, et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2012; 131: 949-55. doi:10.1002/ijc.26470
10. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infect Agent Cancer 2011; 6: 8. doi:10. 1186/1750-9378-6-8
11. Abramowitz L, Jacquard AC, Jaroud F, Haesebaert J, Siproudhis L, Pradat P, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129: 433-9. doi:10.1002/ijc.25671
12. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008; 2: 97-105
13. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66: 1263-71. doi:10.2165/00003495-200666090-00008
14. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04- adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, doubleblind PATRICIA trial. Lancet Oncol 2012; 13: 89-99. doi:10.1016/S1470-2045(11)70286-8
15. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27. doi:10.1056/NEJMoa061741
16. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65. doi:10.1016/S0140-6736(04)17398-4
17. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1: 408-19. doi:10.1158/2159-8290.CD-11-0131
18. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43. doi:10.1056/NEJMoa061760
19. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial. Lancet Oncol 2011; 12: 862-70. doi:10.1016/S1470-2045(11)70213-3
20. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401-11. doi:10.1056/NEJMoa0909537
21. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85. doi:10.10 56/NEJMoa1010971
22. Centres for Disease Control and Prevention (CDC). HIV infection and adult vaccination. Atlanta: CDC; 2014. Available online at: http://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/hiv.html [verified 13 August 2014
23. National Centre for Immunisation Research & Surveillance (NCIRS). Human papillomavirus (HPV). Westmead, NSW: NCIRS; 2013. Available online at: http://www.ncirs.edu.au/immunisation/factsheets/hpv-human-papillomavirus-fact-sheet.pdf [verified 13 August 2014
24. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191: 1442-50. doi:10.10 86/429298
25. Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007; 102: 501-8. doi:10.1590/S0074-0276200 7005000055
26. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20: 595-600. doi:10.1258/ijsa.2009.009126
27. Rodriguez-Barradas MC, Groover JE, Lacke CE, Gump DW, Lahart CJ, Pandey JP, et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996; 173: 1347-53. doi:10.1093/infdis/173.6.1347
28. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20: 2337-44. doi:10.1097/01.aids.0000253361.63578.14
29. MachalekDA,PoyntenM,JinF,FairleyCK,FarnsworthA,GarlandSM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and metaanalysis. Lancet Oncol 2012; 13: 487-500. doi:10.1016/S1470-2045 (12)70080-3
30. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.doi:10.1136/bmj.b2535
31. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55: 197-204. doi:10.1097/QAI.0b013e3181de8d26
32. Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012; 206: 1309-18. doi:10.1093/infdis/jis489
33. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013; 57: 735-44. doi:10.1093/cid/cit319
34. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04- adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31: 5745-53. doi:10.1016/j.vaccine.2013.09.032
35. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202: 1246-53. doi:10.1086/656320
36. Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind, clinical trial. J Infect Dis 2014; 209: 1165-73. doi:10.1093/infdis/jit657
37. The Future I/II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010 341: c3493. doi:10.1136/bmj. c3493
38. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-53. doi:10.1001/jama.298. 7.743
39. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012; 131: 106-16. doi:10.1002/ijc.26362
40. The Future II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196: 1438-46. doi:10.10 86/522864
41. Søgaard OS, Schonheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010; 24: 1315-22. doi:10.1097/QAD.0b013e328339fe0b
42. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444-51. doi:10.1093/jnci/djr319
43. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012; 344: e1401. doi:10.1136/bmj.e1401
44. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105: 28-37. doi:10.10 38/bjc.2011.185
45. US Food and Drug Administration (USFDA). Gardasil. Silver Spring MD: USFDA; 2014. Available online at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042 [verified 13 August 2014
46. European Medicines Agency (EMA). Annex I: summary of product characteristics. London: EMA; 2014. Available online at: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000703/WC500021142.pdf [verified 13 August 2014
47. Therapeutic Goods Administration (TGA). Australian public assessment report for Gardasil. Symonston, ACT: TGA; 2011. Available online at: http://www.tga.gov.au/pdf/auspar/auspargardasil. pdf [verified 13 August 2014
48. Donà MG, Palamara G, Di Carlo A, Latini A, Vocaturo A, Benevolo M, et al. Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men. J Clin Virol 2012; 54: 185-9. doi:10.1016/j.jcv.2012.02.014
49. De Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vezina S, Cote P, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011; 52: 1174-81. doi:10.1093/cid/cir064
50. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-36. doi:10.7326/0003- 4819-148-10-200805200-00005
51. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5: 696-704. doi:10.4161/hv.5.10.9515